Introduction
Mycophenolate mofetil (MMF) is an immunosuppressive agent used in human and companion animal medicine for the treatment of immune-mediated disease. [1] [2] [3] In humans it was initially approved for prevention of renal allograft rejection and its use has since expanded to several other immune-mediated diseases. 1, 3 In companion animals it has been prescribed for the treatment of multiple immune-mediated conditions including, but not limited to, haemolytic anaemia, acquired myasthenia gravis and pemphigus vulgaris. [4] [5] [6] Mycophenolate mofetil is the prodrug of mycophenolic acid (MPA), which acts as an inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is an enzyme crucial to the formation of guanosine, and its inhibition results in a depletion of guanine nucleotides. 1 Cytotoxicity of MPA is specific to T and B lymphocytes. These cells are dependent on the de novo pathway for purine synthesis, while other cell types can utilize a salvage pathway that is lacking in lymphocytes. 1, 2 More specifically, MPA targets the type II isoform of IMPDH which is most abundant in activated lymphocytes. 2 As MMF targets both T and B lymphocytes, it suppresses both cell-mediated and humoral immune responses. 1 Pharmacokinetic studies in humans as well as in the dog reveal rapid oral absorption of the drug with significant enterohepatic circulation. 7, 8 Advantages of using MMF when compared to other adjunct immunosuppressive agents include rapid onset of action and an available parenteral formulation. 4 Mycophenolate is also reported to have reduced myelotoxicity and hepatotoxicity when compared to azathioprine. 4 In spite of this, MMF is not recognized in the veterinary literature as a first choice steroid-sparing agent. Reported adverse effects in dogs include diarrhoea, vomiting, weight loss, allergic reaction (facial swelling and ventral abdominal urticaria after intravenous MMF administration) and papillomatosis. 2, 5, 9 The aim of this retrospective study was to describe the use of MMF as an adjunctive immunosuppressive agent with glucocorticoids in the treatment of canine immunemediated dermatoses such as pemphigus foliaceus, vasculitis, perianal fistula and bullous diseases. It was hypothesized that treatment with MMF as a secondary agent with glucocorticoids would be effective in treating immune-mediated skin disease. In addition, the aim of this study was to report any adverse events associated with administration of the drug.
Materials and methods
This retrospective study was conducted at the University of Tennessee Veterinary Medical Center. Case records from 2010 to 2015 were used to identify dogs with immune-mediated skin diseases that were treated with mycophenolate mofetil. Pet owners had been notified of possible adverse effects of the drug and its lack of approval by the US Food and Drug Administration for use in this species. Inclusion criteria included a diagnosis of idiopathic autoimmune or immune-mediated skin disease including pemphigus foliaceus, vasculitis, vesicular cutaneous lupus erythematosus (VCLE), perianal fistula or subepidermal bullous disease; baseline laboratory evaluation; and at least one re-check appointment. Diagnosis of autoimmune or immune-mediated skin disease was based on consistent clinical signs, cytology, ruling out other differential diagnoses, and confirmation with biopsy and consistent histopathological features. Information acquired and evaluated from the medical record included signalment (age, breed, sex and weight), diagnosis (specific autoimmune or immune-mediated dermatosis), immunosuppressive treatments prior to commencing MMF therapy, other medications, complete blood count, chemistry panel and urinalysis, before and after introduction of MMF, initial dose of MMF, time to remission of disease, maintenance dose of MMF, and adverse events associated with MMF administration. Response was defined as evidence of clinical improvement of lesions (reduction of primary lesions, number of crusts and body area affected, where applicable). Partial remission in pemphigus foliaceus cases was defined as reduction of lesions to several residual crusts restricted to one body region. Remission was defined as clinical resolution of all skin lesions.
Results
The retrospective analysis of case records yielded 14 cases that fulfilled the inclusion criteria (Tables 1 and 2 ). The mean age for dogs studied was 6.3 years (range 0.9-11 years, median 6.5). Table 1) . Two pemphigus cases achieved partial remission (remaining lesions were mild and limited to the face). Treatment was discontinued due to adverse events in the remaining pemphigus case. Mean time to remission in pemphigus cases was 5.8 weeks (range 3-8 weeks, median 6.5).
Full remission was achieved in the dog with epidermolysis bullosa and the dog with VCLE at four and six weeks, respectively ( Table 2 ). There was no response after 4 weeks of treatment in the dog with perianal fistulas and treatment was discontinued. Treatment was discontinued in both the vasculitis and histiocytosis cases because of adverse events. Therapy in these cases lasted two weeks and one week, respectively.
Most dogs achieving remission required concurrent glucocorticoid therapy (n = 6); however, the steroid doses were low when compared to immunosuppressive doses and were administered at a maximum frequency of every other day (Tables 1 and 2 ). The dogs receiving prednisone as maintenance (n = 5) were treated with doses ranging from 0.13 to 1.1 mg/kg. These doses represent maintenance therapy following tapering of original immunosuppressive dosing.
Adverse events were reported in eight of 14 dogs (Tables 1 and 2 ). These included diarrhoea/soft stool, haematochezia, vomiting, probable papilloma formation and neoplasia. Treatment was discontinued as a result of adverse effects in one dog with vomiting and diarrhoea, and in one dog with haematochezia. The remaining cases with gastrointestinal (GI) adverse effects were transient, self-limiting and medically manageable. Probable papilloma formation was noted in one dog and was limited to one lesion. The only concurrent medication in this case was prednisone; therapy was not discontinued. In the vasculitis case, therapy was discontinued due to the diagnosis of histiocytic sarcoma. A single cutaneous mass on the left forelimb was first noted at the start of MMF therapy but was not further evaluated at that time. At the 2 week re-check evaluation, the nodule had increased in size and another nodule was noted, necessitating biopsy and discontinuation of MMF; therefore, we do not believe the neoplasia to be related to MMF treatment. Baseline clinical laboratory evaluations were performed in every animal. Repeat sampling were performed in 12 of 14 cases at 2 weeks and, for cases that remained on therapy, every two to six months depending on clinical signs and previous laboratory findings. Elevated liver enzymes including alkaline phosphatase (ALP) and/or alanine aminotransferase (ALT) were noted in ten of 14 cases prior to commencement of MMF therapy. Mean ALP concentration for those with elevations was 2035.9 U/L with a range of 221-5910 U/L (reference range 13-164 U/L). Mean ALT concentration for those with elevations was 638 U/L with a range of 136-1833 U/ L (reference range 18-100 U/L). In the 12 cases with follow-up samples at 2 weeks, liver enzyme concentrations decreased (mean ALP 1138 U/L, range 79-3560 U/L; mean ALT 256 U/L, range 29-1085 U/L) with tapering of steroid medications.
Discussion
The results of this study support the hypothesis that treatment with MMF as a secondary agent with steroids is effective when treating immune-mediated skin disease and that MMF has minimal adverse effects. Adverse events noted were self-limiting or easily mitigated with symptomatic medications and/or did not lead to discontinuation of therapy, with the exception of two cases with GI signs.
Good efficacy was achieved with MMF treatment for dogs with pemphigus foliaceus, with six of nine cases achieving complete remission. These results conflict with a previously published abstract reporting a case series of eight dogs diagnosed with pemphigus foliaceus and treated with MMF. Only four of eight dogs completed that prospective study due to euthanasia (n = 2), spontaneous remission (n = 1) or change of therapy (n = 1). Of the four dogs completing the study, three experienced excellent reductions in lesional area. 10 Even though concurrent glucocorticoids were used, that study focused on MMF as a first-line therapeutic agent, which may explain the discrepancy in results when compared to the current study, where MMF was used as a second-line and steroid-sparing agent.
Results of the current study report good efficacy in single cases of epidermolysis bullosa aquisita and VCLE. This is consistent with a previously published case report where MMF was used successfully as a second-line immunosuppressive agent in a dog with subepidermal blistering autoimmune disease. 11 A published case series of 11 dogs with vesicular cutaneous lupus erythematosus does not report the use of MMF; however, six of 11 dogs were treated with azathioprine as a second-line immunosuppressive agent with five of those six dogs reported to have at least 75% improvement. 12 Two of the dogs treated with azathioprine experienced signs of marked liver enzyme elevation, although they did not appear to have clinical disease related to these elevations. Considering the results reported in our study, it is conceivable that MMF represents a less toxic alternative to azathioprine for cases with a diagnosis of VCLE.
The one dog with perianal fistula in this study had no response to MMF. No current reports exist describing the use of MMF to treat perianal fistula; however, azathioprine has been used to treat this disease with variable success. One study utilizing azathioprine as a first-line treatment reported full remission in eight of 13 cases; however, bone marrow suppression was encountered frequently (n = 5) and was a limiting factor for treatment in some cases (n = 3). 13 As MMF has a similar mechanism of action, but a lower tendency to suppress bone marrow, further studies evaluating MMF as a treatment for perianal fistula are warranted. While remission rates for this disease are higher using ciclosporin at 69%, it is important to have additional drugs to choose from in cases that are refractory to steroids and/or ciclosporin.
14 Mean time to remission for dogs in the current study was 5.7 weeks (range 3-8 weeks). This result is similar to that in a report in the human literature where time to clinical improvement ranged from 3 to 6 weeks. 3 Remission in dogs with dermatological diseases treated with azathioprine has been reported to be between 3 and 8 weeks, indicating a similar time to effect with MMF. 13, 15 The cases represented in the present study were all dogs that were refractory to immunosuppressive doses of steroids as a monotherapy and, therefore, may represent a subset of patients with severe or unmanageable disease. This should be taken into account with regard to time to remission, as well as efficacy of treatment.
Adverse events were relatively frequent; however, they were mild and transient in most cases. These results were consistent with previous studies of MMF when prescribed as treatment for immune-mediated haemolytic anaemia where the sole adverse event was diarrhoea. 5 There was no evidence of liver toxicity or bone marrow suppression in this prior study. Although increases of ALP and ALT were noted prior to MMF therapy, values decreased at the 2 week re-check. Because of this decrease, the elevations were attributed to previous steroid administration; however, as no further diagnostic tests were performed, other mechanisms of hepatopathy cannot be ruled out as causative. Five of 14 dogs had a mild nonregenerative anaemia on baseline evaluation with no remarkable changes on follow-up visits. It is possible that there were further hepatic or bone marrow changes in the cases with minimal or no follow-up. By comparison, previous studies reviewing azathioprine liver and bone marrow toxicity in dogs reported a toxicity rate of 15%-30% and 8%-13%, respectively.
16,17
There were six cases of diarrhoea and all cases were consistent with a large bowel focus. Mycophenolate has been reported to cause enteric necrosis and subsequent small bowel diarrhoea at high frequency of administration (10-15 mg/kg three times a day).
18 These signs can be severe to the point of fatality, with necropsy results revealing diffuse, erosive to ulcerative enterocolitis, with multifocal cryptitis and crypt necrosis. 18 With twice daily dosing, gastro-intestinal injury appears to respond to the anti-inflammatory effects of metronidazole. Alternatively, in humans it has been reported that metronidazole lowers the plasma concentration of MMF as a result of reduced enterohepatic recirculation.
19 Therefore, it is feasible that the diarrhoea is responsive to lower plasma drug concentrations in addition to its anti-inflammatory properties. These findings should preclude the use of MMF at high or three times a day dosing. Interestingly, in the three cases where MMF was discontinued due to adverse effects in the current study, the doses prescribed (13.2, 14.0 and 15.3 mg/kg twice daily) were consistent with historical dosing recommendations. 5, 6 We should also consider that treatment failure of a patient receiving MMF concurrently with metronidazole may not be drug failure, but could instead be a result of lower plasma drug concentrations of MMF.
One dog in the study was diagnosed with a histiocytic sarcoma after 2 weeks of treatment with MMF. While the neoplastic disease in this case may not be related to the administration of MMF, there are reports in the human literature implying that lymphoma is a possible adverse effect of the drug. 3 In addition to good efficacy and low morbidity of therapy, cost, formulation and availability should also be considered. Previous studies cite high cost as a disadvantage to MMF therapy; however, since the generic formulation has become available in the United States, MMF has become more affordable. While no cases received the parenteral form in this study, the availability of MMF in that formulation is conceivably beneficial for critically ill and hospitalized patients who cannot receive oral medications.
Limitations of the study include its retrospective nature and the small sample size evaluated. Exact initial dosing of steroids was not available in all cases due to insufficient documentation in medical records. Additionally, the variability in concurrent therapies limits interpretation of the results. Although case numbers are too small to draw major conclusions, results suggest that MMF is a viable, low-risk therapeutic option for several immune-mediated skin diseases. Larger retrospective and prospective studies are warranted. R esum e Contexte -Le mycoph enolate mof etil (MMF) est un agent immunosuppresseur lymphocytotoxique utilis e chez l'homme et l'animal de compagnie dans le traitement des maladies a m ediation immune. Le mycoph enolate mof etil est rapport e pour avoir une moindre my elotoxicit e et h epatotoxicit e que l'azathioprine.
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Resumen
Introducci on -El mofetil micofenolato (MMF) es un agente inmunosupresor linfocitot oxico que se utiliza en medicina humana y animal para el tratamiento de enfermedades inmunomediadas. Se ha publicado que el mofetil micofenolato tiene reducida mielotoxicidad y hepatotoxicidad cuando se compara con azatioprina. Objetivos -Se plante o la hip otesis de que el tratamiento con MMF como un agente secundario con glucocorticoides ser ıa eficaz en el tratamiento de enfermedades de la piel inmunomediadas. Adem as, se estudiaron los efectos adversos asociados con el f armaco. Animales -Catorce perros de una poblaci on de un hospital con diagn ostico de enfermedad de la piel inmunomediada. M etodos -Se realiz o una revisi on retrospectiva de los historiales cl ınicos del 2010-2015 para identificar perros con enfermedad de la piel inmunomediada que fueron tratados con MMF. Resultados -Todos los perros fueron tratados con MMF (dosis media de 14,7 mg/kg dos veces al d ıa) en combinaci on con glucocorticoides. Diez de los 14 casos mostraron resultados positivos, con remisi on completa en ocho casos y remisi on parcial en dos casos. El tiempo medio de remisi on fue de 5,7 semanas. La terapia se interrumpi o en un caso (f ıstula perianal), debido a la falta de respuesta. Efectos adversos se observaron en seis casos e incluyeron diarrea (n = 6), hematoquecia (n = 2), v omitos (n = 3) y formaci on de papilomas (n = 1). La terapia se interrumpi o en dos casos con diarrea. El mofetil micofenolato se interrumpi o en un caso adicional debido a un diagn ostico de neoplasia. Todos los dem as eventos adversos fueron autolimitantes o f acilmente controlados m edicamente. No se observ o hepatotoxicidad ni supresi on de la m edula osea. Conclusi on -Este estudio apoya el uso de MMF como un inmunoterap eutico de segunda l ınea en enfermedades de la piel inmunomediadas en perros. e uma droga imunossupressora linfocitot oxica usada em medicina humana e veterin aria para o tratamento de doenc ßas imunomediadas. De acordo com o que e relatado, o micofenolato de mofetila, quando comparado a azatioprina, possui mielotoxicidade e hepatotoxicidade reduzidas. Objetivos -Levantou-se hip otese de que o uso de MMF como agente secund ario em associac ßão com glicocortic oides seria efetivo no tratamento de dermatopatias imunomediadas. Al em disto, efeitos adversos relacionados a droga são relatados. M etodos -Um estudo retrospectivo do arquivo de hist oricos cl ınicos de cães com dermatopatias imunomediadas tratadas com MMF, entre 2010 e 2015. Resultados -Todos os cães tratados com MMF (dose m edia 14,7 mg/kg, a cada 12 horas) em associac ßão com glicocortic oides. Dez de 14 casos demonstraram resultados satisfat orios, com remissão completa em oito casos e parcial em dois. O tempo m edio de remissão foi 5,7 semanas. A terapia foi descontinuada em um caso (f ıstula perianal), devido a resposta pobre. Efeitos adversos foram observados em seis casos e inclu ıram diarreia (n = 6), hematoquezia (n = 2),êmese (n = 3) e formac ßão de papilomas (n = 1). A terapia foi descontinuada em dois casos com diarreia. Micofenolato de mofetila foi descontinuado em mais um caso devido a diagn ostico de neoplasia. Todos os outros efeitos adversos foram auto-limitantes ou facilmente resolvidos medicamente. Hepatotoxicidade e supressão de medula ossea não foram notadas. Conclusão -O estudo legitima o uso de MMF como um agente secund ario na imunoterapêutica em dermatopatias imunomediadas em cães.
